tradingkey.logo

Hims & Hers falls, set for tenth straight day of losses

ReutersFeb 12, 2026 6:45 PM

Shares of telehealth company Hims & Hers Health HIMS.N fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses

Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk's Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator

Co's shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy

Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy "knockoffs" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder

Up to last close, HIMS down 50% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI